Company intelligence / Profile preview

Risklick

Bern, Switzerland

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Risklick has demonstrated that its Protocol AI platform can reduce clinical protocol development times by up to 50% for medicinal products and medical devices. The technology is validated by partnerships with industry leaders such as Debiopharm and ISS AG, who have used and endorsed Protocol AI for improved study planning and regulatory compliance. No clinical drug or device programs are run by Risklick itself, as it is a technology/platform provider rather than a product developer.

Industry: Drug Discovery Services

Partnerships

DebiopharmISS AG (Integrated Scientific Services)DayOne Health 4.0 AcceleratorUniversity of Bern

Beyond the preview

Go deeper on Risklick.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Risklick.

Explore the full profile